1. At a Glance
Healthcare Global Enterprises Ltd (HCG) is one of those companies that sounds heroic on paper—cancer care, fertility, pan-India hospitals, international presence—and then quietly hands you a quarterly loss while trading at a valuation that screams Apollo dreams, penny stock patience.
As of early February, HCG is sitting at a market cap of roughly ₹8,022 crore with the stock wobbling around ₹569, down ~25% over three months. Quarterly revenue came in at ₹633 crore, up a respectable 13.3% YoY, but PAT for the quarter decided to go underground at –₹7.9 crore. Yes, loss. Again.
The kicker? The stock is still valued at ~295x trailing earnings, ROCE is stuck at ~8.6%, ROE is barely 5%, and debt has ballooned to ₹1,768 crore. This is a company running cancer hospitals, not a biotech moonshot—yet the valuation thinks it’s curing mortality itself.
Latest results are Quarterly Results, so EPS logic is locked. Q3 FY26 EPS is –₹0.67. Annualising that would be financial malpractice, so we won’t.
This is a story of scale, capex hunger, promoter change, and a balance sheet that looks like it’s been through chemo itself. Curious already? Good. Let’s go deeper.
2. Introduction
Healthcare Global Enterprises Ltd is not a new kid on the block. It’s been around long enough to see multiple healthcare cycles, funding booms, hospital IPO manias, and private equity mood swings. The company operates under two main brands—HCG for cancer care and Milann for fertility—and positions itself as a specialty healthcare network rather than a generalist hospital chain.
On paper, the narrative is clean: oncology is a high-entry-barrier, capital-intensive business with strong long-term demand tailwinds. Fertility is discretionary but fast-growing. Put them together and you get a “premium healthcare platform.”
In reality, HCG has been running a marathon with ankle weights. Revenue growth has been steady—~16% CAGR over 5 years—but profitability has been erratic. Interest costs are heavy, depreciation keeps climbing thanks to continuous capex, and every expansion seems to arrive before the previous one has fully healed.
FY25 ended with PAT of ₹49 crore, which looked like a comeback. FY26 Q3 said, “Relax, not so fast.” Losses returned, interest costs hit ~₹45 crore per quarter, and depreciation crossed ₹60 crore.
Then came the
